Business Description
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.
Business History
Price Overview
Last updated: Jun 27, 2026 8:59am (just now)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -0.95
Total Equity: $275.68M
Shares: 41,175,725
Total Debt: $9.88M
Cash: $19.95M
EBITDA: -$38.84M
Total Debt: $9.88M
Cash: $19.95M
Revenue: $134.48M
Shares: 41,175,725
Revenue: $134.48M
Revenue: $134.48M
Revenue: $134.48M
Total Equity: $275.68M
Tax Rate: -0.2%
Equity: $275.68M
Total Debt: $9.88M
Cash: $19.95M
Current Liabilities: $26.25M
Long-Term Debt: $9.88M
Total Debt: $9.88M
Total Equity: $275.68M
Shares: 41,175,725
Shares: 41,175,725
CapEx: -$3.83M
Shares: 41,175,725
Stock Price: $5.36
Net Income: -$38.94M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 21, 2026 7:54pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $22.6M | $49.0M | $89.1M | $139.9M | $134.5M |
| Cost of Revenue | $18.1M | $27.7M | $35.3M | $41.0M | $31.5M |
| Gross Profit | $4.5M | $21.3M | $53.8M | $98.9M | $103.0M |
| Operating Expenses | $57.3M | $84.6M | $103.9M | $135.8M | $151.2M |
| Operating Income | -$52.8M | -$63.3M | -$50.1M | -$36.9M | -$48.2M |
| Net Income | -$48.7M | -$66.8M | -$48.6M | -$27.5M | -$38.9M |
| EBITDA | -$41.0M | -$57.8M | -$41.0M | -$23.8M | -$38.8M |
| EPS | $-1.78 | $-2.41 | $-1.41 | $-0.71 | $-0.95 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 7:54pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $24.4M | $11.8M | $9.7M | $16.7M | $19.9M |
| Total Current Assets | $176.3M | $134.6M | $168.4M | $293.8M | $287.5M |
| Total Assets | $192.7M | $150.2M | $182.6M | $318.6M | $311.8M |
| Current Liabilities | $11.1M | $17.2M | $20.9M | $25.9M | $26.3M |
| Long-Term Debt | $39.8M | $40.2M | $0 | $0 | $9.9M |
| Total Liabilities | $54.5M | $60.3M | $22.2M | $37.3M | $36.1M |
| Total Equity | $138.2M | $89.9M | $160.4M | $281.2M | $275.7M |
| Retained Earnings | -$479.3M | -$546.0M | -$594.6M | -$622.1M | -$661.0M |
Cash Flow (Annual)
Last updated: Jun 21, 2026 7:54pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$44.7M | -$58.9M | -$41.6M | -$16.9M | -$15.5M |
| Capital Expenditure | -$1.9M | -$2.4M | -$4.8M | -$5.4M | -$3.8M |
| Free Cash Flow | -$46.6M | -$61.2M | -$46.4M | -$22.4M | -$19.3M |
| Acquisitions (net) | $80.0M | -$42.3M | $17.3M | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $10.7M | -$12.6M | -$2.2M | $7.1M | $3.2M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 1:41am (7h ago)| Metric | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| Revenue |
$131.6M $128.7M – $134.3M
|
$129.2M $127.9M – $130.1M
|
$142.3M $139.0M – $145.3M
|
$155.0M $155.0M – $155.0M
|
| EBITDA |
-$76.8M -$78.4M – -$75.1M
|
-$75.5M -$76.0M – -$74.7M
|
-$83.1M -$84.8M – -$81.1M
|
-$90.5M -$90.5M – -$90.5M
|
| Net Income |
-$42.6M -$46.4M – -$38.9M
|
-$59.0M -$63.7M – -$52.2M
|
-$54.7M -$60.5M – -$45.1M
|
-$50.9M -$55.6M – -$41.2M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 7:54pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +116.9% | +81.8% | +57.1% | -3.9% |
| Gross Profit Growth | +372.2% | +152.1% | +84.0% | +4.1% |
| Operating Income Growth | -19.9% | +20.9% | +26.4% | -30.7% |
| Net Income Growth | -37.1% | +27.2% | +43.5% | -41.8% |
| EBITDA Growth | -40.9% | +29.0% | +42.1% | -63.5% |
Insider Trading (Recent)
All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-17 | Warner Robert Keith | A-Award | 37,037.00 | $0.00 | $0 |
| 2026-06-17 | PALMISANO ROBERT J | A-Award | 37,037.00 | $0.00 | $0 |
| 2026-06-17 | Maniar Shweta | A-Award | 37,037.00 | $0.00 | $0 |
| 2026-06-17 | Fountain Tamara | A-Award | 37,037.00 | $0.00 | $0 |
| 2026-06-17 | LINK WILLIAM J PHD | A-Award | 37,037.00 | $0.00 | $0 |
| 2026-06-17 | Corley Jesse Anderson | A-Award | 37,037.00 | $0.00 | $0 |
| 2026-06-17 | COHEN RAYMOND W | A-Award | 30,864.00 | $0.00 | $0 |
| 2026-06-17 | Tammenoms Bakker Juliet | A-Award | 37,037.00 | $0.00 | $0 |
| 2026-06-17 | Andrews Julie | A-Award | 37,037.00 | $0.00 | $0 |
| 2026-04-17 | Goldshleger Ilya | M-Exempt | 12,489.00 | $4.13 | $51,580 |
| 2026-04-17 | Goldshleger Ilya | M-Exempt | 12,489.00 | $4.13 | $51,580 |
| 2026-02-28 | Wilterding Mark | M-Exempt | 20,441.00 | $0.00 | $0 |
| 2026-02-28 | Wilterding Mark | M-Exempt | 20,441.00 | $0.00 | $0 |
| 2026-02-28 | Wilterding Mark | F-InKind | 8,068.00 | $7.61 | $61,397 |
| 2026-02-27 | Gaines Scott | A-Award | 32,218.00 | $0.00 | $0 |
| 2026-02-28 | Gaines Scott | M-Exempt | 6,261.00 | $0.00 | $0 |
| 2026-02-28 | Gaines Scott | F-InKind | 2,580.00 | $7.61 | $19,634 |
| 2026-02-28 | Gaines Scott | M-Exempt | 1,657.00 | $0.00 | $0 |
| 2026-02-28 | Gaines Scott | M-Exempt | 1,250.00 | $0.00 | $0 |
| 2026-02-28 | Gaines Scott | M-Exempt | 1,500.00 | $0.00 | $0 |
Narrative Economics
market-narrative step).